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Synovial detection and autoantibody reactivity of processed
citrullinated isoforms of vimentin in inflammatory arthritides
K. Tilleman1, K. Van Steendam1, T. Cantaert2, F. De Keyser2, D. Elewaut2 and D. Deforce1
Objectives. To investigate the presence and characteristics of citrullinated vimentin in protein extracts of inflamed synovial tissue.
Methods. Cytosolic protein extracts obtained from RA (n¼ 14) and SpA patients (n¼ 14) were analysed by gel electrophoresis and western
blotting. Citrullinated vimentin isoforms were visualized by a combination of anti-modified citrulline (AMC) staining and anti-vimentin
detections (V9, H-84). This was subsequently confirmed by immunoprecipitation. Autoantibody detection was verified using sera obtained
form RA (n¼ 6) and SpA (n¼ 6) patients.
Results. A specific cluster of spots displayed on the 2D gel images of cytosolic synovial tissue extracts, was identified by mass spectrometry
as vimentin. Interestingly, our results suggested that these isoforms could be the result of caspase cleavage. In addition, these cleaved forms
of vimentin were found to be citrullinated in synovial cytosolic protein extracts of inflammatory arthritides, mainly in RA patients. Caspase-3 is
able to cleave vimentin at amino acid 85. Western blot analysis with a specific antibody against amino acids 1–84 of vimentin (H-84)
confirmed that the citrullinated isoforms of vimentin were lacking this part of the protein. These results were also confirmed by immuno-
precipitation of vimentin derived from cytosolic protein extracts of RA and SpA patients. Furthermore, the presence of autoantibodies against
these citrullinated processed forms of vimentin was found to be predominantly associated with RA patients.
Conclusions. These findings show the presence of processed citrullinated vimentin in inflammatory arthritides, mainly in RA and suggest
a possible origin of the ACPA immune response in RA.
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Introduction
RA and SpA are two frequent forms of inflammatory arthritis
that are both characterized by synovitis, the chronic inflammation
of the SM. As a result, synovial hyperplasia, neovascularization
and the infiltration of lymphocytes and macrophages eventually
leads to the transformation of the SM into an invasive and
destructive tissue, called the pannus [1]. Although there are some
differences in synovial histopathology between RA and SpA [2],
the molecular differences between RA and SpA synovial inflam-
mation remain poorly understood.
The presence of autoantibodies in the sera of patients diagnosed
with inflammatory arthritis reflects the humoral autoimmune
processes occurring during these pathologies. Many autoantibod-
ies directed against a variety of autoantigens have been described
[3], amongst them the Sa antigen (named after the patients name,
which began with ‘Sa’, where specific autoimmunity was described
using this patient’s serum) [4]. Although, Vossenaar et al. [5]
showed that anti-Sa antibodies targeted citrullinated epitopes of
vimentin, information on in vivo citrullinated vimentin, in partic-
ular, in synovial tissue extracts, is scarce.
Vimentin, an intermediate filament which is abundantly
expressed in synovial fibroblasts [6], has long been thought to
solely play a role in the stability of the cytoplasmic architecture
[7]. It is now known that vimentin is a highly dynamic protein
whose assembly and disassembly is regulated by phosphorylation
[8, 9]. In addition, its function stretches far beyond being part of
the cytoskeleton. This was elucidated by Eckes et al. [10] who
observed impaired wound healing in vimentin/ mice by a failure
of mesenchymal contraction.
More recently, studies indicate a possible role for vimentin in
inflammation, since fragments of this protein can be secreted by
activated macrophages during inflammation [11]. Secretion of
vimentin was induced by TNF- and this extracellular vimentin
seemed necessary for efficient killing of bacteria [11]. Cell surface
expression of vimentin peptides has also been observed by
neutrophils undergoing spontaneous apoptosis [12]. The possible
consequence of secreting or presenting vimentin or fragments
of this protein is the development of autoantibodies against this
intermediate filament. Indeed, the presence of anti-vimentin auto-
antibodies in autoimmune diseases like RA has been demon-
strated. Citrullinated vimentin has been identified to be the Sa
antigen in RA [5]. Although the presence of citrullinated vimentin
has been reported in monocytes, macrophages and SF mono-
nuclear cells [13], there are no reports that indicate that the
antigen itself is present in protein extracts of synovial tissue.
In the present study, we wanted to identify and explore the
characteristics of vimentin in synovial tissue protein extracts of
inflammatory arthritides. Our data show that vimentin extracted
from inflamed synovial tissue is displayed as a specific cluster of
spots on 2D images. This cluster contains vimentin fragments
possibly due to the result of caspase-3 cleavage. In addition,
evidence is shown for the presence of processed citrullinated
vimentin in cytosolic protein extracts obtained from synovial
tissue biopsy samples derived from patients with inflammatory
arthritis. Moreover, autoantibodies against these modified vimen-
tin fragments are predominantly associated with RA.
Patients and methods
Patients
Synovial tissue biopsy samples were obtained from patients
undergoing needle arthroscopy of the knee [14] for diagnostic
work-up or for therapeutic reasons. Patients with RA fulfilling the
ACR criteria [15], patients with SpA fulfilling the ESSG criteria
[16] and patients with knee OA fulfilling the ACR criteria [17]
were included in this study. All patients undergoing needle
arthroscopy had active synovitis (RA and SpA) or joint effusions
(OA) of the knee. Serum samples were collected from 10 RA and
10 SpA patients.
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The clinical characteristics of these patients are summarized in
Table S1 (see Supplementary Table S1, available as supplementary
data at Rheumatology Online). The study was conducted after
approval by the local ethics committee. Written informed consent
was obtained from all participating patients. Detailed information
on the samples used in each of the experiments is given in Table S1
(see Supplementary Table S1, available as supplementary data at
Rheumatology Online).
Protein extraction
The cytosolic proteins (hereafter also referred to as the soluble
proteins) were extracted from the synovial tissue samples using the
ReadyPrep Sequential Extraction Kit from Biorad (Hercules, CA,
USA) according to the manufacturer’s instructions. A cocktail of
phosphatase inhibitors containing cantharidin, bromotetramisole,
microcystin LR, sodium orthovanadate, sodium molybdate,
sodium tartrate and imidazole (Sigma, Steinheim, Germany)
was added to each sample. Endonucleases (Sigma, Steinheim,
Germany), protease inhibitors for a broad range of serine, cysteine
and metalloproteases, as well as calpain (Roche Diagnostics,
Mannheim, Germany) were also added to each sample. Before
protein extraction, synovial biopsy samples were transferred to an
Eppendorf tube, washed with phosphate-buffered saline (PBS)
and homogenized for 2min using a Turrax homogenizer (Ika-
Werke, Stanfer, Germany) in buffer I of the ReadyPrep Sequential
Extraction kit (Biorad) containing 40mM Trisbase. Protein
concentrations were measured using the Coomassie Protein
Reagent assay from Pierce (Rockford, IL, USA) according to
the instructions provided by the manufacturer.
Gel electrophoresis
1D gel electrophoresis. Ten micrograms of protein extract
was diluted with sample buffer containing 0.5M Tris–HCl
(pH 6.8), 10% glycerol, 2% SDS, 5% -mercaptoethanol and
incubated at 958C for 5min. The samples were subsequently
subjected to SDS-PAGE (10%, Laemmli) at 150V for 30min
followed by 200V for 1 h. For visualization of citrullinated
proteins, 50g of soluble protein extract was loaded on the
SDS-PAGE. 1D gels were further prepared for western blotting or
specific bands were cut out for mass spectrometric identification.
2D gel electrophoresis. For 2D analysis, 50g of soluble
synovial protein extract was precipitated with cold acetone
overnight at 208C. After centrifugation at 20 000g for 5min,
the pellet was air dried. 2DE was performed as described before
[IPG 3–10 (17 cm)þ 12% SDS-PAGE (Laemmli)] [18]. The gels
were stained with Sypro Ruby (Molecular Probes, Eugene, OR,
USA) and analysed by PD Quest software (Biorad).
For 2D immunoblotting experiments, 40g soluble protein
extract was prepared as described earlier and incorporated in a
linear IPG pH4–7 (11 cm) strip (Biorad) and rehydrated overnight.
After in-gel rehydration, the strips were isoelectrically focused on
the Protean IEF cell (Biorad) at 188C, using 100V for 30min
(linear ramping), 250V for 30min (linear ramping), 500V for 1 h
(linear ramping), 1 kV for 1 h (linear ramping), rapid ramping to
8 kV in 2 h and steady state at 8 kV for 25 kVh. After IEF, the IPG
strips were equilibrated as described before [18], and placed on a
Laemmli 10% (29 : 1) resolving polyacrylamide gel and run in sets
of two at 150V for 30min followed by 60min at 200V.
Western blotting
Protein transfer onto nitrocellulose membranes (Biorad, Hercules,
CA, USA), was performed by tank blotting using the Trans-Blot
Cell (Biorad) at 50V for 3 h. Prior to tank blotting, both the
polyacrylamide gels and nitrocellulose membranes were incubated
in 1 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), pH11
for at least 15min.
Ponceau S visualization of the membranes was conducted to
check the blotting efficiency, and to verify if the 2DE was done
successfully. Blocking was performed for 1 h, using PBS/0.3%
Tween-20 and followed by probing the membrane with patient
sera (1/100 in PBS/0.3% Tween-20) overnight. Immune reactive
spots were detected using horseradish peroxidase (HRP)-labelled
goat anti-human IgG (Pierce) (1/5000 in PBS/0.3%Tween-20) and
visualized by enhanced chemiluminescence (ECL) using the
Supersignal West Dura Extended Duration Substrate from
Pierce. Blots were stripped using the Restore Western Blot
Stripping Buffer (Pierce) at 378C for 30min and re-incubated
with blocking buffer for 1 h. Sufficient stripping was confirmed by
re-probing the membrane with secondary antibody and subse-
quent detection by ECL.
Vimentin was visualized using two antibodies: the clone V9
(Sigma, St Louis, MI, USA): an antibody raised against the
C-terminal end of vimentin, the H-84 polyclonal antibody (Santa
Cruz Biotechnology inc. CA, USA): an antibody raised against
the N-terminus of vimentin (against amino acids 1–84). Both
antibodies were diluted in PBS/0.3% Tween-20 at 1/400 for
V9 and 1/200 for H-84 and incubated overnight. The vimentin
V9 cluster and the head of vimentin (H-84) were visualized by
ECL following incubation with HRP-labelled rabbit anti-mouse
IgG (Pierce) (1/1000 dilution) and HRP-labelled goat anti-rabbit
(1/1000 dilution), respectively, in PBS/0.3% Tween-20 for 1 h.
For fibrinogen- detection, the blots were incubated with rabbit
anti-human fibrinogen B (Cambio, Cambridge, UK) (1/5000 in
blocking solution) after 1 h blocking (5% milk, 0.1% Tween-20 in
PBS) and visualized by ECL using an HRP-labelled goat anti-
rabbit IgG (Pierce) (1/1000 in PBS 0.3% Tween-20) for 1 h.
For the detection of citrullinated proteins, blots were first
stripped as described earlier and subsequently chemically modified
prior to immunostaining using the anti-modified citrulline (AMC)
detection kit (Upstate, Charlottesville, VA, USA) as indicated by
the manufacturer’s instructions.
Protein patterns were scanned and digitized using the VersaDoc
Imaging System (Biorad) and band detection analysis was
performed using Quantity One Analysis Software (Biorad).
Bands were represented as Gaussian models where the Gaussian
model trace, representing the area under the profile curve
calculated in pixel intensitymillimetres (INTmm), was used
to quantify the bands.
For all western blot experiments, negative controls were
included in which the nitrocellulose membranes were incubated
solely with the secondary antibody. In addition, to determine
disease-specific autoantibody reactivity, blots were incubated with
a pool of sera obtained from four healthy individuals.
Immunoprecipitation of vimentin from synovial biopsy tissue
Cytosolic protein extracts of synovial tissue of RA and SpA
patients were pooled to obtain a total amount of 2mg protein
material. The cytosolic protein extract pool of RA and SpA was
concentrated to a volume of 500l using Vivaspin 2 (hydrosart)
spin columns (Sartorius, Goettingen, Germany). The concentrated
protein extracts were pre-cleared by incubating them with protein
G slurry (100l) (Pierce) for 5min. After centrifugation at 10 000g
for 10min at 48C, the supernatant was transferred to another
Eppendorf tube and 100g of anti-vimentin V9 was transferred
to the pre-cleared protein extracts and incubated for 1 h on ice.
Subsequently, the 100l washed protein G slurry was added
and incubated while rotating for 2 h at 48C. After centrifugation
at 10 000g for 1min followed by five washes with PBS, the
protein G slurry pellet was incubated with reducing Laemmli
sample buffer at 958C for 10min. The immunoprecipitated
proteins were stored at 208C until SDS-PAGE and western
blotting.
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Protein identification by mass spectrometry
Spots or bands of interest were excised from the 2D gel or 1D gel,
respectively and digested with modified sequence grade trypsin
(porcine) (Promega, Madison WI, USA) or Lys-C (Sigma,
Steinheim, Germany) and analysed on a Quadrupole Time of
flight (Q-TOF) Ultima mass spectrometer (Waters, Milford, MA,
USA) using matrix assisted laser desorption ionisation (MALDI)
or electrospray ionisation (ESI) as previously described [18].
Processing and database searching of the data against the Swiss-
Prot database was performed by ProteinLynx Global Server
v2.2.5 software (PLGS) (Waters) or with MASCOT daemon and
identified with the MASCOT in house search engine (http://
www.matrixscience.com). During the database search, several
variable modifications were accounted for, including carbamido-
methyl (cys), oxidation (Met) and citrullination (Arg).
In vitro caspase-3 cleavage of vimentin
Human recombinant vimentin (Progen Biotechnik, Heidelberg,
Germany) was cleaved by human recombinant caspase-3
(Chemicon International, Temecula, CA, USA) overnight at
378C at 1U/1g vimentin.
Results
Vimentin is observed as a specific pattern on 2D images of
cytosolic protein extracts of inflammatory synovial tissue
Analysis of the soluble synovial tissue proteome of inflammatory
arthritides revealed a rather specific pattern on the acidic side of
the 2D gel image. This figure consisted of vimentin isoforms,
as confirmed by mass spectrometry (Table 1, Fig. 1).
We focused on two vimentin protein isoform spots, further
referred to as VIM_1 and VIM_2 and indicated on Fig. 1.
Detailed examination of the mass spectrometric data revealed
a clear difference between the higher MW forms VIM_1 and
VIM_2, which was found at a lower MW. For the identification
by ESI-Q-TOF of VIM_2, no peptides were retrieved within the
first 100 amino acids of the protein sequence (see Supplementary
Figure S1A, available as supplementary data at Rheumatology
Online), in contrast with the identification of VIM_1 (see
Supplementary Figure S1B, available as supplementary data at
Rheumatology Online). In addition, MALDI-Q-TOF identifica-
tion of these isoforms confirmed this data. The peptide mass
fingerprint (PMF) responsible for the identification of VIM_1
showed peptides derived from the first 100 amino acids with high
ion count intensity (>50% of total ion count), contrary to the
PMF for VIM_2, where these peptides had very low ion count
intensity (<20% of total ion count) or were absent from the mass
spectrum in multiple analyses (data not shown).
Vimentin has a defined structure consisting of a head, starting
from the second amino acid up to amino acid 95, a body contain-
ing the coils 1A, 1B and coil 2 and a tail (amino acids 408–466)
(see Supplementary Figure S1C, available as supplementary data
at Rheumatology Online) [19]. The mass spectrometric data clearly
showed that the N-terminal head (comprising the first 95 amino
acids) of vimentin form VIM_2 was absent (see Supplementary
Figure S1A, available as supplementary data at Rheumatology
Online).
We reasoned that this may reflect protein processing. It is
known that vimentin is a substrate for caspase cleavage [20].
Indeed, caspase-3 can cleave vimentin at amino acid 85, cleaving
the head from the body of the protein resulting in a cleaved form
of vimentin with theoretical MW¼ 44.5 kDa and pI¼ 4.75. This
form would appear 9 kDa lower than the native form, which
has a MW of 53.5 kDa and would shift towards the acidic side
on a 2D gel as the native form has a pI of 5.06. When comparing
these theoretical characteristics with the experimental data
obtained from the 2D gel (Table 2, Fig. 1), in addition to the
mass spectrometric data, we can assume that VIM_2 is a caspase-3
cleaved form of vimentin.
In vitro caspase-3 cleavage of vimentin
In order to confirm these data, in vitro cleavage of vimentin with
caspase-3 was analysed by 1DE and 2DE. It is known that vimentin
cleavage by caspase-3 gives rise to a fragment at 48 kDa on
SDS-PAGE [20]. 1DE analysis confirmed the caspase-3 cleavage
and indeed showed the appearance of a vimentin isoform at
MW¼ 48 kDa [Fig. 3A (in vitro cleaved vimentin)].
The 2D image showed several cleavage products. However,
they did not show a dramatic shift towards the acidic pI of the
IPG strip (data not shown). Nevertheless, the fragments were
located at the correct MW, at 48 kDa. An explanation could be
that the in vivo cleavage forms of vimentin bear an additional
TABLE 1. Identification of processed vimentin isoforms obtained from soluble
synovial tissue extracts analysed by 2D gel electrophoresis
Spot
(Fig. 1) Name
Peptide sequence
matches by ESI-Q-TOF
Sequence coverage
(%) by MALDI-Q-TOF
a VIME_human (K)VELQELNDR(F) 21.1%
(R)EEAENTLQSFR(Q)
(R)EYQDLLNVK(M)
(R)ISLPLPNFSSLNLR(E)
b VIME_human (K)ILLAELEQLK(G) –
c VIME_human (K)VELQELNDR(F) 14.6%
(K)MALDIEIATYR(K)
d VIME_human (K)FADLSEAANR(N) 38.5%
(K)VELQELNDR(F)
(R)EYQDLLNVK(M)
(K)ILLAELEQLK(G)
(R)ISLPLPNFSSLNLR(E
(R)SLYASSPGGVYATR(S)
(R)EEAENTLQSFR(Q)
e VIME_human (K)VELQELNDR(F) –
(K)ILLAELEQLK(G)
(R)QVDQLTNDK(A)
(R)EEAENTLQSFR(Q)
(R)QDVDNASLAR(L)
(R)ISLPLPNFSSLNLR(E)
(K)FADLSEAANR(N)
(R)EYQDLLNVK(M)
(K)MALDIEIATYR(K)
(R)KVESLQEEIAFLK(K)
f VIME_human (K)VELQELNDR(F) –
(R)EEAENTLQSFR(Q)
(K)ILLAELEQLK(G)
(R)QDVDNASLAR(L)
(R)ISLPLPNFSSLNLR(E)
(K)FADLSEAANR(N)
(R)EYQDLLNVK(M)
(K)MALDIEIATYR(K)
(K)VESLQEEIAFLK(K)
g VIME_human (K)VELQELNDR(F) 16.3%
(R)EEAENTLQSFR(Q)
(R)EYQDLLNVK(M)
(K)MALDIEIATYR(K)
(R)ISLPLPNFSSLNLR(E)
h VIME_human (K)VELQELNDR(F) 52.04%
(K)ILLAELEQLK(G)
(R)QVDQLTNDK(A)
(R)EEAENTLQSFR(Q)
(R)QDVDNASLAR(L)
(R)ISLPLPNFSSLNLR(E)
(K)FADLSEAANR(N)
(R)EYQDLLNVK(M)
(K)MALDIEIATYR(K)
(R)KVESLQEEIAFLK(K)
i VIME_human (K)MALDIEIATYR(K) –
(R)EYQDLLNVK(M)
(R)DNLAEDIMR(L)
‘Spot’ represents the letter indicated on Fig. 1; ‘Name’ indicates the protein name of vimentin
described in the protein identification format of the Swiss-Prot database (http://www.expasy.org/);
Peptides identified by ESI tandem mass spectrometry and protein coverage obtained by peptide
mass fingerprinting are shown; protein spots that were not analysed by MALDI are indicated as ‘-’.
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modification, making these products more acidic. Citrullination,
a modification that changes an arginine to citrulline, is known to
shift proteins towards a more acidic pI [21]. This possibility was
explored by AMC staining of the soluble synovial proteome.
Citrullinated vimentin in soluble protein extracts of
inflammatory arthritides
Pooled synovial tissue extract of four RA patients (RAp1¼ 658–
882–966–947) and four SpA patients (SpAp1¼ 713–524–511–350)
was analysed by 2DE. The proteins were transferred to nitro-
cellulose membranes and the vimentin cluster was first visualized.
Protein citrullination was subsequently analysed by AMC
staining. The vimentin cluster (MW 40–60 kDa, pI 4.7–5.5) was
nicely visualized in both RA and SpA [Fig. 2, Vimentin (V9)].
We observed citrullination of vimentin in these pooled cytosolic
protein extracts of both RA and SpA patients (Fig. 2, AMC).
Besides the vimentin cluster (MW 40–60 kDa, pI 4.7–5.3), two
other spot clusters were found to be citrullinated in cytosolic
protein extracts of inflammatory arthritides (data not shown).
These spot trains were observed at MW 60kDa covering pI
5.1–5.6 and MW 50kDa between pI 5.8–6.2 and were identified by
western blot as fibrinogen- chain (Fig. 2, FIBB). The fibrinogen-
 chain at MW 60kDa and pI 5.1–5.6 overlaps partially with
the high MW forms of vimentin. Since there is some minor citrul-
lination staining in this area, this could be the result of fibrinogen-
 citrullination rather than vimentin citrullination. However, there
is no distinct AMC staining in this particular area on the 2D
image. In addition, it is clear that the citrulline containing protein
spots between MW 40 and 50 kDa are derived from processed
vimentin isoforms as will be shown by additional experiments
described subsequently.
In order to verify patient variability in protein citrullination,
cytosolic protein extracts of RA (n¼ 14), SpA (n¼ 14) and OA
(n¼ 8) patients were subjected separately to SDS-PAGE followed
by western blotting. The vimentin fragments were visualized by
western blotting in all pathologies [Fig. 3A, Vimentin
(V9)_individual patients]. Processed isoforms of vimentin were
present in all pathologies.
Strong AMC staining (Gaussian model trace of most intense
band >1000 INTmm) was observed in 43% of the RA patients,
a weak signal was detected in soluble protein extracts of SpA
patients (Gaussian model trace of most intense band >300
INTmm) and none in OA patients (Gaussian model trace
of most intense band <100 INTmm) (Fig. 3B, AMC_individual
patients).
The strong positive AMC bands corresponded to bands at MW
between 40 and 50 kDa. We wanted to ascertain that the AMC
staining in 1D-PAGE matched vimentin. Therefore, the region
between MW 40 and 60 kDa of the cytosolic protein extract
of synovial tissue of RA882 was cut out from the SDS-PAGE gel,
partitioned in six slices, digested with trypsin or Lys-C and
analysed by mass spectrometry. The slices, between 40 and 50 kDa
contained vimentin as primary identified protein (see Supplemen-
tary Figure S2, available as supplementary data at Rheumatology
Online). Again, no peptides were identified in the first 100 amino
acids of the vimentin sequence, indicating that the identified
isoforms of vimentin were processed forms. Additionally, western
blotting with anti-human vimentin (H-84), an antibody raised
against the first 84 amino acids of vimentin, showed that when
vimentin is cleaved and loses the first part of its amino acid
sequence, no bands appear under the MW of 50 kDa (Fig. 3A,
VIM H-84).
Finally, vimentin was immunoprecipitated from pooled protein
extracts of RA, SpA and OA. AMC staining confirmed that the
positive AMC reactivity seen in the 1D-PAGE of RA and SpA
patients is derived from vimentin (Fig. 3B, IP vimentin). AMC
staining of immunoprecipitated vimentin showed bands at MW
60kDa, and two bands between MW 40 and 50 kDa.
The results of the immunoprecipitations showed that the
citrullinated processed forms of vimentin are present both in
RA and SpA. However, the intensity of the bands is lower in SpA
patients than RA patients suggesting an enrichment of citrulli-
nated vimentin in RA.
This immunoprecipitation experiment was confirmed in
another pool of RA and SpA patients and in addition, no
citrullinated vimentin could be immunoprecipitated from synovial
tissue extracts of OA patients (data not shown).
Autoantibody reactivity of in vitro synovial citrullinated
vimentin fragments
Citrullinated vimentin has been described as a potential autoanti-
gen in RA; therefore, autoantibody reactivity was examined by
immunoblotting.
Incubations with individual serum samples (n¼ 12) (see
Supplementary Table S1, available as supplementary data at
Rheumatology Online) were analysed on 2D blots containing
a pool of soluble synovial protein extracts of RA (969–882–
966–947). In order to verify the autoantibody reactivity to the
exact forms of cleaved vimentin, the blots were landmarked with
narrow lines. After serum incubation, the nitrocellulose mem-
branes were stripped and re-probed with anti-human vimentin
in order to visualize the vimentin cluster. Using the landmarks,
exact positioning of the autoimmune spots within the vimentin
cluster was possible. These spots were indicated by ‘þ’ on the
image. For easy interpretation of the data, the position of the
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FIG. 1. Raw 2D image of the cytosolic proteome of synovial tissue obtained from
a knee biopsy sample of a patient diagnosed with SpA. The vimentin cluster is
organized in a specific figure on the 2D image of the synovial tissue soluble protein
extract. Spots that were analysed by mass spectrometry are indicated from (a)
to (i). The green spots represent VIM_1 and VIM_2.
TABLE 2. Theoretical and experimental 2D characteristics of vimentin isoforms
Full length (Vim_1) Cleaved (Vim_2) (VIM_1–VIM_2)
pIth (pH) 5.06 4.75 0.31
MWth (Da) 53 520.19 44 534.56 8985.63
pIexp (pH) 5.00 4.63 0.37
MWexp (Da) 57 300 49 300 8000
‘pIth’ and ‘MWth’: the theoretical isoelectric point and molecular weight calculated from the
amino acid sequence of the full length protein as indicated in the Swiss-Prot database; ‘pIexp’ and
‘MWexp’: the experimental isoelectric point and molecular weight obtained from the position on
the 2D gel; ‘(VIM_1–VIM_2)’: difference in characteristics between VIM_1 and VIM_3
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vimentin cluster is indicated on each blot displaying the auto-
immune reactivity of the patient’s sera (Fig. 4).
As a control for disease-specific autoantibody reactivity, blots
were incubated with a serum pool obtained from four healthy
individuals, in which minor immune reactivity against the high
MW forms of vimentin was observed (Fig. 4). This reactivity was
considered not disease specific and is indicated in blue on the blots.
In the 2D immunoblotting experiment, we observed a different
immune reactive pattern in serum derived from RA CCP patients
in comparison to RA CCPþ (cyclic citrullinated peptides) patients.
In contrast to RA CCP patients (0/3 patients showed autoanti-
body reactivity against vimentin), there was a distinct reactivity
of RA CCPþ sera against processed forms of synovial vimentin
(3/3 showed positive autoantibody reactivity). When blots were
probed with individual SpA serum, only the serum of one SpA
patient out of six was considered as positive autoantibody
reactivity against vimentin fragments. The blots probed with
serum of other patients were negative or the signal was only
slightly above the background noise level.
The data shown in Fig. 4 are representative for each group.
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FIG. 2. Detection of processed citrullinated vimentin in inflammatory arthritides by 2DE. Forty micrograms of a pool of soluble synovial tissue protein extract was subjected
to 2DE (IPG 4–7, 10% SDS-PAGE) and transferred to nitrocellulose membrane. Detection of vimentin [Vimentin (V9)], AMC staining (AMC) and fibrinogen- (FIBB)
are shown.
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Discussion
We investigated the properties of vimentin in inflammatory
synovial tissue and showed that citrullinated vimentin was present
in cytosolic protein extracts of knee synovial tissue obtained
from patients with inflammatory arthritides. It is known that upon
in vitro citrullination, vimentin is irreversibly disassembled resulting
in an accumulation of soluble vimentin oligomers [22]. This could
explain in part the lack of previous observations of citrullinated
vimentin in synovial protein extracts as most extracts des-
cribed in literature are ureum–dithiothreitol (DTT) extracts [23].
These ureum–DTT extracts are enriched in deiminated fibrin, the
most frequently studied deiminated protein in synovial tissue [23].
In addition, the synovial cytosolic citrullinated vimentin
appeared to be a collection of processed fragments of the protein.
The processing of vimentin can occur by caspase cleavage during
the event of apoptosis [20]. It is known that within 2 h of apoptosis
induction, when the majority of the cells are still viable, a 48 kDa
fragment of vimentin appears as the result of a caspase-3 like
cleavage releasing the N-terminal head of the protein [20]. In our
proteome study, the low MW isoform of vimentin appeared
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FIG. 3. Detection of processed citrullinated vimentin inflammatory arthritides by SDS-PAGE and immunoprecipitation. (A) Individual patient protein extracts were analysed
by western blot on which vimentin was detected with two different antibodies [(V9) or (H-84)]; in vitro capase-3 cleavage of vimentin was run as a positive control for the
appearance of the 48 kDa fragment. (B) Individual AMC staining of RA, SpA and OA patients (AMC_individual) is analysed and citrullination of processed vimentin is
confirmed by immunoprecipitation in RA and SpA (IP vimentin_pooled).
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at 48 kDa. In addition, careful interpretation of the mass
spectrometric data revealed the absence of peptides, which
originated from the head of the protein (consisting of amino
acids 1–95). We therefore concluded that the N-terminal head of
vimentin was lacking, possibly by caspase-3 cleavage. When
in vitro caspase-3 cleavage of vimentin was performed and
subjected to 2DE, we observed multiple cleavage fragments.
However, we could not observe any fragments shifting towards
the acidic pI. As this was in contrast with the in vivo 2D image of
synovial citrullinated vimentin, where fragments of vimentin were
observed shifting towards the acidic side of the IPG strip, we
investigated the presence of citrullinated residues in these
fragments by AMC staining.
Vimentin fragments did appear to be citrullinated in cytosolic
synovial protein extracts of inflammatory arthritis patients.
Immunoprecipitation of synovial soluble vimentin confirmed
these results. It has been indicated that citrullination of proteins
is not specific for RA, but inherent to chronic inflammation of the
synovial tissue. Previous reports showed that deiminated fibrin
can be found in synovial protein extracts of other arthritides [24].
In agreement with these studies, this report demonstrates citrullin-
ated vimentin in synovial soluble protein extracts of both RA and
SpA patients, although there appears to be an enrichment of these
modified vimentin isoforms in RA. Studies on larger patient
cohorts are needed in to order to confirm this observation.
A specific enrichment of citrullinated vimentin could be the result
of a less effective clearing of apoptotic cells. Indeed, citrullination
of proteins has been associated with apoptosis [25–27] and more
specifically, it has been shown that vimentin is selectively and
rapidly citrullinated in macrophages undergoing apoptosis [27].
Additionally, activated macrophages secrete fragments of vimen-
tin [11] and also neutrophils undergoing spontaneous apoptosis
express fragments of the C-terminal tail of vimentin on their
surface [12]. Whether these vimentin fragments are citrullinated
has not been determined yet. It is possible that citrullination of
vimentin is the only way towards a direct and irreversible disas-
sembly of vimentin filaments resulting in cytoskeleton disruption
leading to cell shrinkage in the process of apoptosis [20]. There-
fore, citrullination of vimentin could be an early event in the
processing of the protein as the disassembly of the intermediate
filament by citrullination could be necessary for further processing
of the protein by caspases or other proteases. The exact sequence
of events, however, is not known.
The specific autoantibody reactivity against processed citrulli-
nated vimentin was also investigated. Autoantibody reactivity
against the processed and modified forms of vimentin could be
detected in RA. RA CCPþ sera reacted strongly with low MW
citrullinated vimentin isoforms, whereas in RA CCP and SpA,
this reactivity was absent or extremely weak. Additional studies
on large-scale cohorts of RA and control groups including SpA
still need to be conducted to determine the sensitivity and specif-
icity of the autoantibodies against processed forms of vimentin.
Recently, the development of the anti-mutated citrullinated
vimentin (anti-MCV) ELISA [28] has made it possible to analyse
the specificity and sensitivity of the anti-Sa antibodies. Several
groups have evaluated the clinical relevance of this test and con-
clude that the performance of the anti-MCV test in the diagnosis
of RA is similar to that of the anti-CCP2 test [29–31]. Antibodies
against citrullinated vimentin have been shown to be significantly
associated with erosive disease outcome, whereas anti-CCP anti-
bodies were not significant predictors [32]; however, these results
need further confirmation in larger patient cohorts.
It is well known that antibodies against citrullinated proteins
(ACPA) are highly specific for RA [33, 34]. The presence of ACPA
is significantly related to HLA-DR shared epitope (SE) [35, 36]
and this can be explained by the fact that MHC with SE has a high
affinity for negatively charged or uncharged polar amino acids,
while positively charged amino acids inhibit peptide binding [37].
Therefore, when arginine is deiminated, the positive charge is
converted to a polar but uncharged residue increasing the affinity
in the binding pocket. This was shown by Hill et al. [38] where
conversion of an arginine into citrulline in the N-terminal head of
vimentin increased peptide affinity and resulted in CD4þ T-cell
activation in HLA-DR4-IE transgenic mice.
In conclusion, we reported on processed vimentin isoforms in
the cytosolic proteome of inflammatory arthritides. Our data
suggest that these isoforms are probably the result of caspase
cleavages. The enrichment of citrullinated vimentin isoforms in
the synovium could serve as a possible origin of the ACPA
immune response in RA.
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FIG. 4. Presence of autoantibodies against vimentin in inflammatory arthritides. Soluble synovial tissue extracts of a pool of RA patients (969–882–966–947) was subjected
to 2D immunoblotting. In order to verify that the autoantibody reactivity was against vimentin, the blots were stripped and vimentin was detected. Immune reactive spots
indicated by (þ) correlated to vimentin isoforms subsequently detected on the same membranes. Reactivity of healthy sera is indicated in blue and should be regarded as
non-disease specific. CCP() sera showed no reactivity for vimentin in contrast with CCP(þ) RA sera in which strong positive detection of vimentin isoforms was observed.
In SpA patients, autoantibody reactivity against cleaved products of vimentin was rather weak to absent. Serum samples of six RA and six SpA patients were individually
incubated and the displayed figures are results that are representative for sera of the same pathology.
Rheumatology key messages
 Processed vimentin is citrullinated in synovial cytosolic protein
extracts of inflammatory arthritides.
 The presence of citrullinated vimentin isoforms indicates a
possible origin of the ACPA immune response in RA.
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